HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research-Reference-Cited by-同舟云学术

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research

Published:2016-09-16 Issue:12 Volume:139 Page:2859-2864
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Pietrantonio F.¹,Caporale M.¹,Morano F.¹,Scartozzi M.²,Gloghini A.³,De Vita F.⁴,Giommoni E.⁵,Fornaro L.⁶,Aprile G.⁷,Melisi D.⁸,Berenato R.¹,Mennitto A.¹,Volpi C. C.³,Laterza M. M.⁴,Pusceddu V.²,Antonuzzo L.⁵,Vasile E.⁶,Ongaro E.⁷,Simionato F.⁸,de Braud F.¹⁹,Torri V.¹⁰,Di Bartolomeo M.¹

Affiliation:

1. Medical Oncology Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy

2. Medical Oncology Department; Azienda Ospedaliera Universitaria Cagliari, Presidio Policlinico Universitario “Duilio Casula”; Cagliari Italy

3. Diagnostic pathology and laboratory medicine Department; Fondazione IRCCS Istituto Nazionale dei Tumori; Milan Italy

4. Medical Oncology Department; Seconda Università degli studi di Napoli; Naples Italy

5. Medical Oncology 1, Azienda Ospedaliera Universitaria Careggi; Florence Italy

6. U.O. Oncologia Medica 2 Universitaria, Ospedale S. Chiara - Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano; Tumori Italy

7. Medical Oncology Department; University and General Hospital; Udine Italy

8. Medical Oncology, Università degli studi di Verona; Italy

9. Oncology Department; University of Milan; Italy

10. Oncology Department; IRCCS-Mario Negri Institute for Pharmacological Rresearch; Milan Italy

Funder

the Associazione Italiana per la Ricerca sul Cancro (AIRC)

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference24 articles.

1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial;Bang;Lancet,2010

2. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN-a randomized, phase III study;Satoh;J Clin Oncol,2014

3. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC);Kang;J Clin Oncol,2016

4. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer;Leo;J Clin Oncol,2008

5. Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients;Guarneri;Ann Oncol,2013

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies;Cancers;2024-08-15

2. HER2-targeted therapies beyond breast cancer — an update;Nature Reviews Clinical Oncology;2024-07-22

3. Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms;Blood;2024-07-11

4. Mechanisms of resistance to trastuzumab in HER2-positive gastric cancer;CHINESE J CANCER RES;2024

5. HER2-directed therapy following ctDNA-identified ERBB2 amplification in patients with advanced gastroesophageal cancer: exploration of real-world outcomes;ESMO Gastrointestinal Oncology;2024-06